Pneumology and Pulmonary Cell Research, Department of Biomedicine and Internal Medicine, University Hospital Basel, Basel, Switzerland.
Ther Clin Risk Manag. 2014 Jun 13;10:449-53. doi: 10.2147/TCRM.S39710. eCollection 2014.
Chronic obstructive pulmonary disease (COPD) is increasing worldwide and is predicted to become the third most frequent cause of death by 2030. Muscarinic receptor antagonists, alone or in combination with long-acting β2-agonists, are frequently used for COPD therapy. Aclidinium bromide is a novel muscarinic receptor antagonist, and clinical studies indicate that its metabolism is more rapid than that of other muscarinic receptor inhibitors, so systemic side effects are expected to occur less frequently. Aclidinium bromide is well tolerated, and when compared with other muscarinic receptor antagonists, the drug achieves better control of lung function, especially night-time symptoms in COPD patients. This review summarizes the safety profile and side effects reported by recent clinical studies using aclidinium bromide alone.
慢性阻塞性肺疾病（COPD）在全球范围内呈上升趋势，预计到 2030 年将成为第三大最常见死因。单独使用或与长效β2-激动剂联合使用毒蕈碱受体拮抗剂是 COPD 治疗的常用方法。阿地溴铵是一种新型的毒蕈碱受体拮抗剂，临床研究表明其代谢速度快于其他毒蕈碱受体抑制剂，因此预计会较少发生全身性副作用。阿地溴铵具有良好的耐受性，与其他毒蕈碱受体拮抗剂相比，该药物能更好地控制肺功能，尤其是 COPD 患者的夜间症状。本综述总结了近期使用阿地溴铵单药治疗的临床研究报告的安全性概况和副作用。
